Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
CC transcript

ORASURE TECHNOLOGIES INC (OSUR) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 4 Datin James A (Director) has filed a Form 4 on ORASURE TECHNOLOGIES INC
Txns: Granted 3,922 shares @ $5.71, valued at $22.4k
Paid exercise price by delivering 1,062 shares @ $5.71, valued at $6.1k
08/17/2023 4 Anthony Michele Marie (SVP Finance & CAO) has filed a Form 4 on ORASURE TECHNOLOGIES INC
Txns: Sold 1,758 shares @ $6.5, valued at $11.4k
Exercised 1,758 options to buy @ $5.71, valued at $10k
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/10/2023 4 McGrath Kenneth J (CFO) has filed a Form 4 on ORASURE TECHNOLOGIES INC
Txns: Paid exercise price by delivering 12,524 shares @ $6.49, valued at $81.3k
08/04/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/04/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/03/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "OraSure Reports Q2 ‘23 Revenue of $85.4 Million&#59; Core Revenue Grows 3% Year-over-Year InteliSwab® test revenue of $47.5 million in Q2"
08/02/2023 8-K/A Submission of Matters to a Vote of Security Holders  Interactive Data
08/01/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/01/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
07/20/2023 8-K Quarterly results
06/30/2023 4 Datin James A (Director) has filed a Form 4 on ORASURE TECHNOLOGIES INC
Txns: Granted 4,004 shares @ $4.995, valued at $20k
Paid exercise price by delivering 1,084 shares @ $4.995, valued at $5.4k
06/06/2023 4 EGLINTON MANNER CARRIE (President & CEO) has filed a Form 4 on ORASURE TECHNOLOGIES INC
Txns: Paid exercise price by delivering 47,211 shares @ $5.48, valued at $258.7k
05/31/2023 4 McGrath Kenneth J (CFO) has filed a Form 4 on ORASURE TECHNOLOGIES INC
Txns: Bought 100,000 shares @ $4.9281, valued at $492.8k
05/17/2023 4 Aspinall Mara G. (Director) has filed a Form 4 on ORASURE TECHNOLOGIES INC
Txns: Paid exercise price by delivering 5,400 shares @ $5.615, valued at $30.3k
Granted 24,517 shares @ $0
05/17/2023 4 Datin James A (Director) has filed a Form 4 on ORASURE TECHNOLOGIES INC
Txns: Paid exercise price by delivering 5,418 shares @ $5.615, valued at $30.4k
Granted 19,802 shares @ $0
05/17/2023 4 Marmora Lelio (Director) has filed a Form 4 on ORASURE TECHNOLOGIES INC
Txns: Paid exercise price by delivering 6,000 shares @ $5.615, valued at $33.7k
Granted 19,802 shares @ $0
05/17/2023 4 Shulkin David (Director) has filed a Form 4 on ORASURE TECHNOLOGIES INC
Txns: Paid exercise price by delivering 5,014 shares @ $5.615, valued at $28.2k
Granted 19,802 shares @ $0
05/17/2023 4 Whitaker Anne Clem (Director) has filed a Form 4 on ORASURE TECHNOLOGIES INC
Txns: Paid exercise price by delivering 4,400 shares @ $5.615, valued at $24.7k
Paid exercise price by delivering 2,323 shares @ $5.3025, valued at $12.3k
05/17/2023 4 Gagliano Nancy J (Director) has filed a Form 4 on ORASURE TECHNOLOGIES INC
Txns: Granted 19,802 shares @ $0
05/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "ORASURE TECHNOLOGIES, INC. STOCK AWARD PLAN ARTICLE 1 ESTABLISHMENT AND PURPOSE Establishment. Epitope, Inc. established this Plan as the Epitope, Inc. 2000 Stock Award Plan, effective as of February 15, 2000, and the Plan was approved by shareholders of Epitope, Inc. at the 2000 annual shareholders meeting. Effective September 29, 2000, in connection with the merger of Epitope, Inc. with and into OraSure Technologies, Inc., the name of the Plan was changed to the OraSure Technologies, Inc. 2000 Stock Award Plan and the Plan was adopted as a stock award plan of OraSure Technologies, Inc. The Plan was amended and restated, subject to shareholder approval, effective May 16, 2006. The Plan was amended further, subject to shareholder approval, effective May 13, 2008. The Plan again was amended..."
05/12/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "OraSure Reports 1Q23 Record Revenue of $155.0 Million; Announces New Collaborations as Company Increasingly Focuses on Core Growth InteliSwab® test revenue of $118.3 million in Q1, up 33% sequentially; Company delivers cost savings and begins to taper InteliSwab® test production and expenses Gross margins increase 200 basis points sequentially despite mix/pricing headwinds Signs three new molecular partnerships supporting cancer diagnostics, women’s health testing, and microbiome services Q1 GAAP EPS of $0.37; Non-GAAP EPS of $0.47 Improved cash position with $112.4 million in cash and cash equivalents; Company anticipates additional favorable impact from working capital in 2023 Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET BETHLEHEM, PA, May 10, 2023 – OraSure..."
04/27/2023 PX14A6G Form PX14A6G - Notice of exempt solicitation submitted by non-management:
04/14/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/14/2023 ARS Form ARS - Annual Report to Security Holders:
04/14/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/06/2023 4 Datin James A (Director) has filed a Form 4 on ORASURE TECHNOLOGIES INC
Txns: Granted 3,090 shares @ $6.4725, valued at $20k
Paid exercise price by delivering 837 shares @ $6.4725, valued at $5.4k
03/27/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/27/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/14/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "OraSure Reports 4Q22 Record Revenue of $123.1 Million Growing 94% Year-Over-Year; Positions for Longer-Term Growth and Profitability InteliSwab® revenue of $88.9 million in Q4, up 12% sequentially; wins two new federal government contracts extending the tail on InteliSwab® revenue Signs a deal with Quest Diagnostics Genomic Sequencing Services for saliva collection kits Q4 GAAP EPS of $0.21; Non-GAAP EPS of $0.36 Announces restructuring expected to result in operating expense savings of $15 million to be fully implemented by June 2023; targets achieving cash flow breakeven for core business by end of 2024 Cash balance grows to $111 million, up $9 million from prior quarter Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET BETHLEHEM, PA, February 14, 2023 – OraSure ..."
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 7.1% stake in OraSure Technologies Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy